ARA-290 10 mg
Educational recon guide for a 10 mg ARA-290 (cibinetide) research vial mapped to daily SC amounts used in published study designs. Research use only.
Vial
10 mg
Your BAC water
2 mL
Concentration
5.00 mg/mL
Per unit
~50.0 mcg
Frequency
Once daily subcutaneous (commonly 28 consecutive days in trials)
Route
Subcutaneous
Live reconstitution calculator
Defaults match this guide (10 mg + 2 mL BAC). Change water or dose and the unit tables below update automatically.
Step 1
Reconstitution
Peptide amount in the vial and how much bacteriostatic water you add.
Step 2
Your dose
Quick-select common research doses (includes 2.5 / 7.5 for dual-agonist ladders) or type any mg / mcg value.
Quick select (mg) — switch units or type any value
Suggested: 30-unit barrel (smallest that fits this draw).
Your draw
Results
Total draw
20 units
Volume
0.200 mL
Doses per vial
10
Syringes needed
1
Barrel
30-unit
Fits one syringe?
Yes
30-unit · 0.3 mL
Filled to 20 u
Fill one 30-unit U-100 syringe to about 20 units (0.200 mL).
Research cycle phases
Units and volumes recompute from your Step 1 concentration (2 mL BAC → 5.00 mg/mL · 50.0 mcg/unit). Doses below are once daily during the course — not weekly.
Standard course
Published dose-ranging used 1 mg, 4 mg, or 8 mg SC daily for 28 days; 4 mg/day is a frequently cited reference dose.
| Phase | Daily dose | Units | Volume |
|---|---|---|---|
| Days 1–7 (intro · 1 mg) | 1 mg1,000 mcg | 20 u | 0.20 mL≈20 units @ 2 mL recon |
| Days 8–28 (standard · 4 mg) | 4 mg4,000 mcg | 80 u | 0.80 mL≈80 units @ 2 mL recon |
Alternate / higher courses
Shorter or higher daily courses discussed in research communities — not a clinical recommendation
| Phase | Daily dose | Units | Volume |
|---|---|---|---|
| Higher trial arm · 8 mg daily × 28 | 8 mg8,000 mcg | 160 u | 1.60 mL≈160 units — split syringes or use 1 mL BAC |
| Full 28-day · 4 mg from day 1 | 4 mg4,000 mcg | 80 u | 0.80 mLPrefer 100-unit syringe |
Supplies planner
Using the guide’s phase ladder (1 mg → 4 mg per injection (phase ladder)) over a 28-day course. Set a dose in Step 2 to plan supplies at your own amount.
Your recon
2 mL · 5.00 mg/mL
Dose in plan
Phase ladder
Syringe size
100-unit
Horizon
28-day course
ARA-290 10 mg vials
10 vials
~91 mg mg total peptide over this 28-day course at 1 mg → 4 mg per injection (phase ladder). Each vial holds 10 mg.
Bacteriostatic water
7 × 3 mL or 2 × 10 mL
2 mL BAC per vial × 10 vials = 20.0 mL total. Buy as 7× 3 mL bottles or 2× 10 mL bottles (whichever you stock).
U-100 insulin syringes (100-unit)
28+ syringes
About one 100-unit syringe per injection for this schedule. Keep a few spares.
Alcohol swabs & sharps
~76 swabs · 1 sharps container
Wipe vial stopper and injection site each time. Dispose needles in a proper sharps container.
Reconstitution steps
- Allow the lyophilized 10 mg ARA-290 vial and bacteriostatic water to reach room temperature.
- Draw 2.0 mL bacteriostatic water (default for this guide).
- Inject BAC slowly down the inner wall of the vial — avoid blasting the powder cake.
- Gently swirl or roll until the solution is clear. Do not shake hard (foaming).
- Label with recon date and concentration (e.g. "5.0 mg/mL — 2 mL BAC").
- Refrigerate at 2–8 °C (35–46 °F), protected from light. Prefer using a reconstituted multi-dose vial within ~28 days with sterile technique.
Storage
Lyophilized
Keep dry powder cold and dark when possible (−20 °C / −4 °F preferred for long-term research stock).
Reconstituted
Refrigerate at 2–8 °C (35–46 °F). Avoid freeze–thaw of the working solution. Prefer finishing within ~28 days.
- ·Write recon date and BAC volume on the label.
- ·Protect from light during storage.
- ·Discard if cloudy, particulates, or odd odor appear after reconstitution.
Protocol notes
- ·ARA-290 (cibinetide) is an EPO-derived peptide engineered toward innate repair receptor pathways.
- ·Trial designs are short courses (often 28 days).
- ·Research use only.
Research context & considerations
Cibinetide/ARA-290 has been studied in small-fiber neuropathy and related innate-repair literature.
- ·Injection-site reactions can occur.
- ·Not FDA-approved for consumer research-vial use as a medicine.
- ·Pregnancy and breastfeeding are outside research-hobby scope.
Catalog match
ARA290 (Cibinetide)
10mg x 10 vials · from $30